Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests. Researchers found that the drugs, called Hsp90 inhibitors, specifically target and inactivate a mechanism commonly used by prostate cancer cells to evade the effects [...]
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups: Paclical/Apealea in combination with [...]
Calls are ongoing for Northern Ireland to follow Scotland’s lead in which Pharmaceutical Price Regulation Scheme (PPRS) payments are going into a new medicines fund that covers treatments for rare and end-of-life conditions, the Belfast Telegraph reports. Implemented in 2014, the PPRS enables the pharmaceutical sector to make payments to the government depending on the [...]
Patients receiving cancer treatment could increase their chance of survival by up to 20 per cent and help stop their cancer from spreading by taking a low-dose of aspirin, new Cardiff University research suggests. In a systematic review of the available scientific literature a team from the university’s School of Medicine found a significant reduction [...]
Health researchers at Robert Gordon University (RGU) have been awarded funding of almost £10,000 to investigate whether Scottish plants could hold the key to increasing the effectiveness of cancer drugs and boosting survival rates. A research team led by Dr Gemma Barron has received £9,800 from medical research funding charity Tenovus Scotland Grampian for an 18 -month project which [...]
Health and Social Services (HSSD) in Jersey have signed a contract with JAC to roll out their Chemotherapy Management System (CMS) product in the oncology department at The General Hospital to improve the service provided to cancer patients. The General Hospital is a 250-bed hospital based in St Helier and serves the whole island, with a [...]
The pancreatic cancer drug Abraxane will continue to be available in Wales despite a decision by the National Institute for Health and Care Excellence (NICE) to not recommend its use in the NHS, Health and Social Services Minister Mark Drakeford has announced. In September 2014, the All-Wales Medicines Strategy Group (AWMSG) appraised Abraxane for the [...]
Bristol-Myers Squibb has announced that the Scottish Medicines Consortium (SMC) has issued guidance which does not recommend the use of Opdivo®q (nivolumab) as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. The decision will leave Scottish patients with advanced skin cancer without access to this potentially life-extending medicine. In contrast, the [...]
A new report from business intelligence provider GBI Research - Frontier Pharma: Breast Cancer states that the breast cancer treatment pipeline's exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages, may significantly alter the clinical and commercial landscape of the disease market over the next decade. The factors driving [...]
Eisai has criticised strongly NHS England (NHSE) for further delaying access to a number of new cancer treatments. This failure is a result of the implementation by NHSE of a new Cancer Drugs Fund (CDF), following a consultation NHSE confirmed at their board meeting. Those new licensed drugs that have been denied access since May [...]
